Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.91 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PGD | P52209 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL28120184 | 1.00 | PDE4A (0.91) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL27472789 | 0.95 | PDE4A (0.91) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL27672177 | 0.95 | PDE4A (0.91) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL28705777 | 0.95 | PDE4A (0.91) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL16592174 | 0.95 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL15339348 | 0.95 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL13056936 | 0.95 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL19257183 | 0.95 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL21778048 | 0.95 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL16609838 | 0.95 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1464 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114246953-B | Anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2024-07-09 | — | — | CN | claimed |
| EP-3837273-A1 | IMPROVED PROTEIN RECOVERY | Bristol-Myers Squibb Company (US) | 2021-06-23 | — | — | EP | claimed |
| US-20210171573-A1 | IMPROVED PROTEIN RECOVERY | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-10 | — | — | US | claimed |
| WO-2020036903-A1 | IMPROVED PROTEIN RECOVERY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-20 | — | — | WO | claimed |
| EP-4519316-A1 | NEW FORMULATION OF ANTI VISTA ANTIBODY | PIERRE FABRE MEDICAMENT (FR) | 2025-03-12 | — | — | EP | disclosed |
| US-12043663-B2 | Anti-TNF-alpha-antibodies and functional fragments thereof | TILLOTTS PHARMA AG (CH) | 2024-07-23 | — | — | US | disclosed |
| WO-2024151978-A1 | IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024152014-A1 | FGFR3 BINDING MOLECULES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-3456738-B1 | ANTIBODY VARIANTS | TILLOTTS PHARMA AG (CH) | 2024-07-17 | — | — | EP | disclosed |
| CN-118355031-A | Anti-saccharide-LAMP 1 antibodies and uses thereof | GO医疗股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118354789-A | Anti-glyco-cMET antibodies and uses thereof | GO医疗股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-4396232-A1 | ANTI-GLYCO-LAMP1 ANTIBODIES AND THEIR USES | Go Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-1989007945-A1 | HUMAN RELAXIN FORMULATION | GENENTECH, INC. (US) | 1989-09-08 | — | — | WO | disclosed |
| WO-1989004177-A1 | GAMMA INTERFERON FORMULATION | GENENTECH, INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0284249-A1 | Lyophilized lymphokine composition | INTERFERON SCIENCES, INC. (US) | 1988-09-28 | — | — | EP | disclosed |
| US-4675184-A | VIRICIDES | 501 Sunstar Kabushiki Kaisha (JP) | 1987-06-23 | — | — | US | disclosed |
| EP-0080879-B1 | PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON IN STABLE STATE | SUNSTAR KABUSHIKI KAISHA (JP) | 1986-10-01 | — | — | EP | disclosed |
| US-4605555-A | INTERFERON, POLYHYDRIC SUGAR ALCOHOL, ORGANIC ACID BUFFER | SUN STAR KABUSHIKI KAISHA (JP) | 1986-08-12 | — | — | US | disclosed |
| US-4605556-A | APPLYING INTERFERON, POLYHYDRIC SUGAR ALCOHOL, AND ORGANIC ACID BUFFER | SUN STAR KABUSHIKI KAISHA (JP) | 1986-08-12 | — | — | US | disclosed |
| EP-0080879-A2 | Pharmaceutical composition containing interferon in stable state | SUNSTAR KABUSHIKI KAISHA (JP) | 1983-06-08 | — | — | EP | disclosed |